{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045000","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.836685+00:00","generated_at":"2026-05-30T06:15:42.473650+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909","bullets":["Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.","Cash $267.4M as of Sept 30, 2024; expects cash runway into 2027.","First patient dosed with FHD-909 (SMARCA2 inhibitor) in Phase 1 for SMARCA4 mutant NSCLC.","Topline Phase 1 data for FHD-286 + decitabine in AML expected by year-end 2024.","Appointed Anna Rivkin as Chief Business Officer in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045000","json":"https://secwatch.observer/filing/0001628280-24-045000.json","markdown":"https://secwatch.observer/filing/0001628280-24-045000.md","text":"https://secwatch.observer/filing/0001628280-24-045000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/0001628280-24-045000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/fhtx-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:15:42.473650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}